Literature DB >> 12570792

Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists.

Agostino Molteni1, William F Ward, Chung H Ts'ao, JoAnn Taylor, William Small, Loredana Brizio-Molteni, Patricia A Veno.   

Abstract

Angiotensin converting enzyme (ACE) inhibitors and angiotensin II (AII) type 1 receptor antagonists have strong cytostatic properties on in vitro cultures of many normal and neoplastic cells. They are effective, in particular, in reducing the growth of human lung fibroblasts, renal canine epithelial cells, bovine adrenal endothelial cells, simian T lymphocytes, and of neoplastic cell lines derived from human neuroblastomas, a ductal pancreatic carcinoma of the Syrian hamsters, human salivary glands adenocarcinomas, and two lines of human breast adenocarcinomas. ACE inhibitors are also effective in protecting lungs, kidneys and bladders from the development of nephropathy, pneumopathy, cystitis, and eventually fibrosis in different models of organ-induced damage such as exposure to radiation, chronic hypoxia, administration of the alkaloid monocrotaline or bladder ligation. ACE inhibitors and AII type 1 receptor antagonists are also effective in reducing excessive vascular neoformation in a model of injury to the cornea of rats and rabbits, and in controlling the excessive angiogenesis observed in the Solt-Farber model of experimentally induced hepatoma, in methylcholantrene or radiation-induced fibrosarcomas, in radiation-induced squamous cell carcinomas and in the MA-16 viral-induced mammary carcinoma of the mouse. Captopril was, in addition, effective in controlling tumor growth in a case of Kaposi's sarcoma in humans. The inhibition of AII synthesis and/or its blockade by AII receptors is likely to be an important mechanism for this cytostatic action. The mitogenic effect of AII is well established and a reduction of AII synthesis may well explain cell and neoplasm delayed growth. Moreover, AII regulates and enhances the activity of several growth factors including transforming growth factor B (TGFB) and smooth muscle actin (SMA); and many of these factors are reduced in tissues of animals treated with ACE inhibitors and AII type 1 receptor antagonists. These processes seem to be particularly relevant in the control of fibroblast growth and in the control of the ensuing fibrosis. The ACE inhibitors containing a sulphydril (SH) or thiol radical in their moiety (Captopril and CL242817) seemed to be more effective in controlling fibrosis and the growth of some neoplastic cells than those ACE inhibitors without this thiol radical in their structure, even if the second group of these drugs show in vitro a stronger inhibitory effect on converting enzyme activity. Pharmacologically it is known that ACE inhibitors containing a thiol radical also have antioxidant properties and they are efficient in controlling metalloproteinase action. However, although these additional properties are pharmacologically relevant, the blockade of AII synthesis plays an essential role in the cytostatic activity of these two categories of drugs. These observations underline that in addition to the beneficial effect of these drugs on the cardiovascular system, new potential applications are opening for their wider deployment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12570792     DOI: 10.2174/1381612033455396

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  12 in total

Review 1.  Renin-angiotensin system blockers and modulation of radiation-induced brain injury.

Authors:  M E Robbins; W Zhao; M A Garcia-Espinosa; D I Diz
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

2.  Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways.

Authors:  Ivan G Gomez; Deidre A MacKenna; Bryce G Johnson; Vivek Kaimal; Allie M Roach; Shuyu Ren; Naoki Nakagawa; Cuiyan Xin; Rick Newitt; Shweta Pandya; Tai-He Xia; Xueqing Liu; Dorin-Bogdan Borza; Monica Grafals; Stuart J Shankland; Jonathan Himmelfarb; Didier Portilla; Shiguang Liu; B Nelson Chau; Jeremy S Duffield
Journal:  J Clin Invest       Date:  2014-11-21       Impact factor: 14.808

Review 3.  Radiation-induced cognitive impairment--from bench to bedside.

Authors:  Dana Greene-Schloesser; Mike E Robbins
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

4.  Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer.

Authors:  Denise M Boudreau; Onchee Yu; Jessica Chubak; Heidi S Wirtz; Erin J Aiello Bowles; Monica Fujii; Diana S M Buist
Journal:  Breast Cancer Res Treat       Date:  2014-02-21       Impact factor: 4.872

5.  Cardiovascular medication use and risk for colorectal cancer.

Authors:  Denise M Boudreau; Elizabeth Koehler; Stephen J Rulyak; Sebastien Haneuse; Robert Harrison; Margaret T Mandelson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-10-28       Impact factor: 4.254

6.  Ramipril mitigates radiation-induced impairment of neurogenesis in the rat dentate gyrus.

Authors:  Kenneth A Jenrow; Stephen L Brown; Jianguo Liu; Andrew Kolozsvary; Karen Lapanowski; Jae Ho Kim
Journal:  Radiat Oncol       Date:  2010-02-01       Impact factor: 3.481

7.  The AT1 receptor antagonist, L-158,809, prevents or ameliorates fractionated whole-brain irradiation-induced cognitive impairment.

Authors:  Mike E Robbins; Valerie Payne; Ellen Tommasi; Debra I Diz; Fang-Chi Hsu; William R Brown; Kenneth T Wheeler; John Olson; Weiling Zhao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-10       Impact factor: 7.038

8.  Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.

Authors:  Phunchai Charatcharoenwitthaya; Jayant A Talwalkar; Paul Angulo; Andrea A Gossard; Jill C Keach; Janice L Petz; Roberta A Jorgensen; Keith D Lindor
Journal:  Dig Dis Sci       Date:  2009-03-03       Impact factor: 3.199

9.  The involvement of angiotensin type 1 and type 2 receptors in estrogen-induced cell proliferation and vascular endothelial growth factor expression in the rat anterior pituitary.

Authors:  Hanna Lawnicka; Dorota Ptasinska-Wnuk; Slawomir Mucha; Jolanta Kunert-Radek; Marek Pawlikowski; Henryk Stepien
Journal:  ScientificWorldJournal       Date:  2012-04-26

10.  Association of angiotensin-converting enzyme inhibitor therapy and comorbidity in diabetes: results from the Vermont diabetes information system.

Authors:  Maria E Ramos-Nino; Charles D Maclean; Benjamin Littenberg
Journal:  BMC Endocr Disord       Date:  2008-12-05       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.